Using Modeled Plasmodium Vivax Prevalence Data to Estimate the Market Size for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Tests in Order to Support Decision-Making on Service Delivery Models

Plasmodium vivax causes over 100 million infections annually; 8-aminoquinoline drugs can clear the parasites, but may also cause hemolysis in patients with G6PD deficiency. PATH developed GeoDX, a computer program that estimates the P. vivax burden per health facility, the total quantity of G6PD tests per country, and associated costs.

Publication date: November 2017

Using Modeled Plasmodium Vivax Prevalence Data to Estimate the Market Size for Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency Tests in Order to Support Decision-Making on Service Delivery Models

472.8 KB PDF

Hard copies are not available.

View Resource